Imaging of Inflammation and Treatment: Basic and Translational Potential

炎症成像和治疗：基础和转化潜力

• 批准号: 7869350
• 负责人: XUEDING WANG
• 金额: $ 32.24万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-10 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7869350
• 关键词: Affect; Affinity; Animals; Antirheumatic Agents; Arthritis; Biocompatible; Blood; Blood Volume; California; Chemical Engineering; Clinical; Contrast Media; Development; Devices; Diagnostic Imaging; Disease; Disease model; Drug Delivery Systems; Drug Evaluation; Drug Kinetics; Elements; Engineering; Environment; Etanercept; Evaluation; FDA approved; Functional Imaging; Gold; Human; Hypoxia; Image; Imagery; Imaging technology; Incidence; Inflammation; Inflammatory; Joints; Label; Laboratory Animals; Laboratory Study; Lasers; Life; Light; Magnetic Resonance Imaging; Malignant Neoplasms; Medical; Medical Imaging; Medicine; Metabolic; Methods; Michigan; Modeling; Molecular; Molecular Target; Monitor; Nuclear; Optics; Pain; Pattern; Peripheral; Pharmaceutical Preparations; Pharmacologic Substance; Physiological; Play; Proteins; Radiology Specialty; Rattus; Research; Research Personnel; Resolution; Resources; Rheumatoid Arthritis; Rheumatology; Role; Route; Schools; Signal Transduction; Speed; Synovitis; System; Techniques; Technology; Testing; Therapeutic; Therapeutic Agents; Time; Tissues; Transducers; Treatment Efficacy; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors; Ultrasonic Transducer; Ultrasonography; United States National Institutes of Health; Universities; Work; absorption; base; clinical practice; cytokine; design; disease diagnosis; hemodynamics; imaging modality; improved; in vivo; innovation; instrument; instrumentation; interest; intravenous administration; medical schools; molecular imaging; nanocolloid; nanorod; novel; optical imaging; overexpression; polyvinylidene fluoride; response; soft tissue; subcutaneous; success; time use; tomography; tool; treatment effect; uptake

DESCRIPTION (provided by applicant): The therapy and diagnosis of diseases at the cellular and molecular levels will be improved greatly with the development of medical imaging technologies that can not only monitor the delivery of analytical probes or therapeutic agents but also enable comprehensive and objective evaluation of treatment effects. As an emerging noninvasive, nonionizing light-based technology presenting both high contrast and high spatial resolution, photoacoustic tomography (PAT) may be developed into a novel and promising molecular imaging modality which will generate innovations and play a critical role in medicine. We propose to investigate an even more advanced spectroscopic PAT (SPAT) technique using inflammatory arthritic disease models, patterned after widely known, very costly, painful, and disabling disorders, for demonstration of the method. SPAT, when aided by a newly developed gold nanocolloid contrast agent, may create innovations with an extensive impact in various biomedical applications, not only in more efficient evaluation of drug effects in living laboratory animals but also in optimized therapeutic decisions in clinical practice. The SPAT system for human/animal inflammatory arthritis will be developed on a stand-alone commercial ultrasound unit which, in an exclusive research mode allows acquisition of light-induced ultrasound signals with 64 independent channels simultaneously. This capability will for the first time enable near real-time 2D PAT and fast speed 3D PAT. Gold nanorods with the optical absorption peak tuned to the NIR region will be conjugated with Etanercept (Enbrel(r)), an FDA approved drug for rheumatoid arthritis. Due to the strong optical absorption by gold nanorods, the SPAT system working with a designed PVDF array transducer holds promise in imaging the drug uptake in regional arthritic tissues. Besides drug delivery monitoring, the unique ability of SPAT in evaluating treatment efficacy will also be examined through the comparison with nuclear imaging and MRI conducted on the same animals quasi-simultaneously. By imaging the morphological and physiological hallmarks of synovitis including hypervascularization and hypoxia, SPAT may realize comprehensive evaluation of the early responses of arthritic tissues to the pharmaceutical treatment. This research is anticipated to develop instrumentation and techniques that may significantly contribute to diagnostic imaging and therapeutic monitoring of various disorders including inflammatory diseases and cancer.

描述（申请人提供）：随着医学成像技术的发展，在细胞和分子水平上对疾病的治疗和诊断将大大提高，这些技术不仅可以监测分析探针或治疗剂的输送，还可以对治疗效果进行全面客观的评价。光声层析成像技术（PAT）作为一种新兴的无创、非电离、高对比度、高空间分辨率的光成像技术，有可能成为一种新的、有前途的分子成像方式，在医学领域将产生创新和发挥关键作用。我们建议研究一种更先进的光谱PAT （SPAT）技术，使用炎症性关节炎疾病模型，以众所周知的、非常昂贵的、痛苦的和致残的疾病为模型，来证明该方法。在一种新开发的金纳米胶体造影剂的帮助下，spv可能会在各种生物医学应用中产生广泛影响的创新，不仅在活体实验动物中更有效地评估药物效果，而且在临床实践中优化治疗决策。用于人类/动物炎症性关节炎的SPAT系统将在一个独立的商业超声单元上开发，该单元以独特的研究模式允许同时获取64个独立通道的光诱导超声信号。该功能将首次实现近实时2D PAT和快速3D PAT。具有光学吸收峰调谐到近红外区域的金纳米棒将与依那西普（Enbrel(r)）偶联，依那西普是FDA批准的治疗类风湿性关节炎的药物。由于金纳米棒具有很强的光吸收能力，该系统与设计的PVDF阵列换能器一起工作，有望对局部关节炎组织的药物摄取进行成像。除了药物递送监测外，还将通过与核成像和核磁共振成像（MRI）在同一动物上的准同时进行比较，来检验SPAT在评估治疗效果方面的独特能力。通过对滑膜炎的形态学和生理学特征（包括血管增生和缺氧）进行成像，可以全面评估关节炎组织对药物治疗的早期反应。这项研究预计将开发仪器和技术，可能对包括炎症性疾病和癌症在内的各种疾病的诊断成像和治疗监测做出重大贡献。